De vertaling van deze pagina is experimenteel en in ontwikkeling. Uw is welkom!

Poxel Beheer

Beheer criteriumcontroles 3/4

De CEO Poxel's is Thomas Kuhn, benoemd in Mar2009, heeft een ambtstermijn van 15.58 jaar. bezit rechtstreeks 3.19% van de aandelen van het bedrijf, ter waarde € 614.59K. De gemiddelde ambtstermijn van het managementteam en de raad van bestuur bedraagt respectievelijk 15.7 jaar en 9.6 jaar.

Belangrijke informatie

Thomas Kuhn

Algemeen directeur

n/a

Totale compensatie

Percentage CEO-salaris	n/a
Dienstverband CEO	15.6yrs
Eigendom CEO	3.2%
Management gemiddelde ambtstermijn	15.7yrs
Gemiddelde ambtstermijn bestuur	9.6yrs

Recente managementupdates

Recent updates

Poxel S.A. (EPA:POXEL) Analysts Just Trimmed Their Revenue Forecasts By 28%

Mar 27

Is Poxel (EPA:POXEL) Weighed On By Its Debt Load?

May 07

How Much Did Poxel's(EPA:POXEL) Shareholders Earn From Share Price Movements Over The Last Five Years?

Dec 16

How Does Poxel's (EPA:POXEL) CEO Pay Compare With Company Performance?

Nov 17

Analyse CEO-vergoeding

Hoe is Thomas Kuhn's beloning veranderd ten opzichte van Poxel's winst?
Datum	Totale vergoeding	Salaris	Bedrijfswinsten
Jun 30 2023	n/a	n/a	-€44m
Mar 31 2023	n/a	n/a	-€38m
Dec 31 2022	€852k	€300k	-€31m
Sep 30 2022	n/a	n/a	-€30m
Jun 30 2022	n/a	n/a	-€29m
Mar 31 2022	n/a	n/a	-€26m
Dec 31 2021	€1m	€296k	-€24m
Sep 30 2021	n/a	n/a	-€26m
Jun 30 2021	n/a	n/a	-€28m
Mar 31 2021	n/a	n/a	-€30m
Dec 31 2020	€1m	€271k	-€32m
Sep 30 2020	n/a	n/a	-€30m
Jun 30 2020	n/a	n/a	-€28m
Mar 31 2020	n/a	n/a	-€27m
Dec 31 2019	€478k	€230k	-€26m
Sep 30 2019	n/a	n/a	-€21m
Jun 30 2019	n/a	n/a	-€16m
Mar 31 2019	n/a	n/a	-€7m
Dec 31 2018	€433k	€206k	€1m
Sep 30 2018	n/a	n/a	-€2m
Jun 30 2018	n/a	n/a	-€5m
Mar 31 2018	n/a	n/a	-€14m
Dec 31 2017	€489k	€191k	-€22m

Compensatie versus markt: Er zijn onvoldoende gegevens om vast te stellen of de totale vergoeding van Thomas redelijk is in vergelijking met bedrijven van vergelijkbare omvang in de French markt.

Compensatie versus inkomsten: De vergoeding van Thomas is het afgelopen jaar in lijn geweest met de bedrijfsprestaties.

CEO

Thomas Kuhn

15.6yrs

Tenure

€852,112

Compensatie

Mr. Thomas Kuhn, PharmD, MBA co-founded Poxel SA in 2009 and serves as its Chief Executive Officer and its Director since June 23, 2010. Mr. Kuhn joined Merck Serono in 2000, where he held various position...

Leiderschapsteam

Naam	Positie	Tenure	Compensatie	Eigendom
Thomas Kuhn	Co-Founder	15.6yrs	€852.11k	3.19% € 614.6k
Sébastien Bolze	Co-Founder	15.8yrs	geen gegevens	geen gegevens
Pascale Fouqueray-Grellier	Co-Founder and Executive VP of Clinical Development & Regulatory Affairs	15.8yrs	geen gegevens	geen gegevens
Sophie Hallakou-Bozec	Co-Founder and Executive VP of R&D Pharmacology & Scientific Communication	15.8yrs	geen gegevens	geen gegevens
Arthur Rouille	Investor Relations Officer	no data	geen gegevens	geen gegevens
Quentin Durand	Executive VP	5.1yrs	geen gegevens	geen gegevens
Sylvie Bertrand	Vice President of Human Resources	3yrs	geen gegevens	geen gegevens

15.7yrs

Gemiddelde duur

Ervaren management: Het managementteam van POXEL is doorgewinterd en ervaren (gemiddelde ambtstermijn van 15.7 jaar).

Bestuursleden

Naam	Positie	Tenure	Compensatie	Eigendom
Thomas Kuhn	Co-Founder	14.3yrs	€852.11k	3.19% € 614.6k
Richard Kender	Independent Director	9.8yrs	€108.06k	geen gegevens
Harold Lebovitz	Member of Scientific Advisory Board	no data	geen gegevens	geen gegevens
Pascale Boissel	Independent Director	9.6yrs	€74.00k	geen gegevens
Mohammed Baluch	Independent Chairman of the Board	12yrs	€105.06k	geen gegevens
Ralph Defronzo	Member of Scientific Advisory Board	5.8yrs	geen gegevens	geen gegevens
Masato Kasuga	Member of Scientific Advisory Board	5.7yrs	geen gegevens	geen gegevens
John Amatruda	Member of Scientific Advisory Board	no data	geen gegevens	geen gegevens
Wataru Ogawa	Member of Scientific Advisory Board	no data	geen gegevens	geen gegevens
Kohjiro Ueki	Member of Scientific Advisory Board	no data	geen gegevens	geen gegevens
Hirotaka Watada	Member of Scientific Advisory Board	no data	geen gegevens	geen gegevens
Kohei Kaku	Member of Scientific Advisory Board	5.8yrs	geen gegevens	geen gegevens

9.6yrs

Gemiddelde duur

Ervaren bestuur: De raad van bestuur van POXEL wordt beschouwd als ervaren (gemiddelde ambtstermijn 9.6 jaar).

Poxel Beheer

Beheer criteriumcontroles 3/4

Belangrijke informatie

Recente managementupdates

Poxel S.A., Annual General Meeting, Jun 21, 2023

Insufficient new directors

Poxel S.A., Annual General Meeting, Jun 21, 2022

Insufficient new directors

Insufficient new directors

Insufficient new directors

Recent updates

New major risk - Financial data availability

New major risk - Shareholder dilution

New major risk - Shareholder dilution

Sumitomo Pharma and Poxel Announce Topline Results from Post-Marketing Clinical Study on TWYMEEG for the Treatment of Type 2 Diabetes in Japan

New major risk - Shareholder dilution

New minor risk - Financial data availability

New major risk - Revenue and earnings growth

Forecast to breakeven in 2024

New major risk - Share price stability

First half 2023 earnings released

Poxel S.A. to Report Q2, 2023 Results on Sep 26, 2023

Consensus revenue estimates decrease by 43%

Poxel S.A., Annual General Meeting, Jun 21, 2023

Consensus revenue estimates decrease by 13%

Consensus revenue estimates fall by 32%

Poxel S.A. to Report Q3, 2023 Results on Nov 08, 2023

Insufficient new directors

Consensus forecasts updated

First half 2022 earnings released

Poxel S.A. Announces Positive Results from Phase 2 NASH Trial (DESTINY-1) for PXL065, A Novel, Proprietary Deuterium-Stabilized R-Stereoisomer of Pioglitazone

Price target decreased to €11.50

Consensus forecasts updated

Full year 2021 earnings: EPS exceeds analyst expectations while revenues lag behind

Consensus forecasts updated

Poxel S.A. Announces Pxl065 and Pxl770 Granted Orphan Drug Designation from the U.S. Fda for X Linked Adrenoleukodystrophy

Poxel S.A., Annual General Meeting, Jun 21, 2022

Price target decreased to €13.43

Insufficient new directors

Poxel Announces PXL770 Wins FDA Fast Track Designation for X-Linked Adrenoleukodystrophy

Insufficient new directors

Consensus revenue estimates fall by 28%

Poxel S.A. (EPA:POXEL) Analysts Just Trimmed Their Revenue Forecasts By 28%

Insufficient new directors

Poxel Announces PXL065 Granted FDA Fast Track Designation for X-Linked Adrenoleukodystrophy

First half 2021 earnings released

POXEL SA Completes Enrollment in Phase 2 NASH Trial for PXL065 (DESTINY-1) in Biopsy-Proven Patients

Poxel and Sumitomo Dainippon Pharma Announce Product Launch in Japan for TWYMEEG® as Treatment for Type 2 Diabetes

Poxel S.A. Announces New Strategic Direction with Increasing Focus on Rare Metabolic Diseases

Consensus forecasts updated

Poxel Presents Results of Two Clinical Studies on Its Direct Amp Kinase Activator, the Pxl770

Poxel SA and Sumitomo Dainippon Pharma Co., Ltd. Announces Approval of TWYMEEG for Treatment of Type 2 Diabetes in Japan

Poxel S.A. Presents New Results of Imeglimin Phase 2 and 3 Clinical Studies in Japan at the 64th Annual Meeting of the Japan Diabetes Society (JDS)

Is Poxel (EPA:POXEL) Weighed On By Its Debt Load?

Full year 2020 earnings released

New 90-day high: €7.62

Poxel S.A. Terminates Partnership Agreement with Metavant

Poxel S.A. to Report Q3, 2021 Results on Oct 20, 2021

Price target lowered to €15.83

How Much Did Poxel's(EPA:POXEL) Shareholders Earn From Share Price Movements Over The Last Five Years?

Poxel Announces Additional Positive Phase 2a Results, and Phase 2b Plan for PXL770, an Oral First-in-Class AMPK Activator, in NASH

Poxel Provides Update on Metavant Partnership with Imeglimin

Poxel Presents Phase 1b Clinical Results for PXL065 and New Preclinical Data for PXL770 at AASLD The Liver Meeting 2020

How Does Poxel's (EPA:POXEL) CEO Pay Compare With Company Performance?

New 90-day high: €7.19

New 90-day low: €6.00

Poxel Announces Positive Results From Phase 2a NASH Trial With PXL770, an Oral First-in-Class Direct AMPK Activator

Poxel S.A. Presents Imeglimin Phase 3 TIMES Results and PXL770 Preclinical Cardio-Renal Results at the 56th European Association for the Study of Diabetes Annual Meeting

First half earnings released

New 90-day low - €6.13

New 90-day low - €6.38

Analyse CEO-vergoeding

CEO

Tenure

Compensatie

Leiderschapsteam

Gemiddelde duur

Bestuursleden

Gemiddelde duur